Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Comfort Systems USA Inc (FIX) vs Eli Lilly And Co (LLY) Price & Performance

Comfort Systems USA IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Comfort Systems USA Inc vs Eli Lilly And Co — how do they compare? Comfort Systems USA Inc trades at $1,726.05 (market cap $60.06B), while Eli Lilly And Co trades at $1,169.35 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 17.3× Comfort Systems USA Inc's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 41 Days and Eli Lilly And Co for 93 Days on average.

FIXLLY
Market Cap
$60.06B$1.04T
Volume
371,8963,064,878
Sector
IndustrialsHealth
52-Week High
$2.07K$1.28K
52-Week Low
$790.72$799.57
Typical Hold Time
41 Days93 Days
Enterprise Value
$58.53B$1.09T
Dividend Yield
0.21%0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Comfort Systems USA Inc

Comfort Systems USA (FIX) trades at $1,741.36, down 4.21% today but maintains strong technical momentum with bullish moving averages and support at $1,712. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $12.53 vs. $10.45, while revenue growth accelerates from $9.1B in 2025 to $11.2B in 2026. Recent acquisition of Hunt Electric adds $250M in annual revenue, positioning FIX to capitalize on data center and infrastructure demand.

FIX presents a compelling growth opportunity with 55.56% analyst buy ratings and a $2,080 consensus price target offering 19% upside. Key risks include execution challenges in integrating acquisitions and potential margin pressure from rising costs. The stock's premium valuation (P/E 42) requires sustained earnings growth, but strong ROE (55.29%) and expanding data center backlog support the bullish case.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.

Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FIX
51% Buy49% Sell
Avg holding period · 41 Days
LLY
69% Buy31% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About Comfort Systems USA Inc

Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.

Read more on FIX →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →